Schedule A


Fund	Date	Transaction	Number of shares	Price
Pivotal bioVenture Partners Fund I, L.P.	02/17/2026	Sale	510	$4.9893(1)
NFLS Beta Limited	02/17/2026	Sale	290	$4.9893(1)
Pivotal bioVenture Partners Fund I, L.P.	02/18/2026	Sale	5,076	$4.6478(2)
NFLS Beta Limited	02/18/2026	Sale	2,891	$4.6478(2)
Pivotal bioVenture Partners Fund I, L.P.	02/19/2026	Sale	4,751	$4.8762(3)
NFLS Beta Limited	02/19/2026	Sale	2,685	$4.8762(3)
Pivotal bioVenture Partners Fund I, L.P.	02/20/2026	Sale	828	$5.1386(4)
NFLS Beta Limited	02/20/2026	Sale	472	$5.1386(4)
Pivotal bioVenture Partners Fund I, L.P.	02/23/2026	Sale	956	$4.9775(5)
NFLS Beta Limited	02/23/2026	Sale	544	$4.9775(5)
Pivotal bioVenture Partners Fund I, L.P.	02/24/2026	Sale	828	$5.0017(6)
NFLS Beta Limited	02/24/2026	Sale	472	$5.0017(6)
Pivotal bioVenture Partners Fund I, L.P.	02/25/2026	Sale	3,228	$4.9799(7)
NFLS Beta Limited	02/25/2026	Sale	1,838	$4.9799(7)
Pivotal bioVenture Partners Fund I, L.P.	02/26/2026	Sale	9,748	$4.6604(8)
NFLS Beta Limited	02/26/2026	Sale	5,552	$4.6604(8)

1 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.93 to $5.03 inclusive. The reporting persons undertake to provide the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range

2 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.50 to $5.15 inclusive. The reporting persons undertake to provide the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range

3 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.70 to $5.25 inclusive. The reporting persons undertake to provide the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range

4 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.03 to $5.23 inclusive. The reporting persons undertake to provide the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range

5 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.92 to $5.04 inclusive. The reporting persons undertake to provide the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range

6 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.92 to $5.12 inclusive. The reporting persons undertake to provide the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range

7 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.90 to $5.07 inclusive. The reporting persons undertake to provide the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range

8 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.52 to $5.11 inclusive. The reporting persons undertake to provide the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range

Bolt Biotherapeutics, Inc. SCHEDULE 13D/A